BIIB
Biogen Inc. NASDAQ Listed Sep 17, 1991$196.58
-1.05%
vs $198.67
Mkt Cap $29.0B
52w Low $121.05
88.9% of range
52w High $205.97
50d MA $190.48
200d MA $174.70
P/E (TTM)
22.3x
EV/EBITDA
10.2x
P/B
1.6x
Debt/Equity
0.4x
ROE
9.3%
P/FCF
14.1x
RSI (14)
50.60
ATR (14)
$6.03
Beta
0.16
50d MA
$190.48
200d MA
$174.70
Avg Volume
1.1M
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
225 Binney Street · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | TNS | 3.05 | 3.57 | +17.0% | 194.38 | -0.2% | -2.6% | -1.2% | +0.1% | +1.0% | +0.8% | — |
| Feb 6, 2026 | TNS | 1.63 | 1.99 | +22.1% | 201.18 | -0.7% | -3.7% | -2.5% | +1.2% | +2.2% | +0.5% | — |
| Oct 30, 2025 | TNS | 3.88 | 4.81 | +24.0% | 149.61 | -1.1% | +3.1% | -1.8% | -1.4% | +2.7% | +2.2% | — |
| Jul 31, 2025 | TNS | 3.90 | 5.47 | +40.3% | 128.00 | +0.8% | +3.1% | +0.2% | +0.5% | -2.7% | -1.2% | — |
| May 1, 2025 | TNS | 2.90 | 3.02 | +4.1% | 120.93 | +1.2% | +2.1% | -1.4% | -4.1% | +0.3% | +1.0% | — |
| Feb 12, 2025 | TNS | 3.43 | 3.44 | +0.3% | 133.43 | -1.0% | +3.8% | -0.8% | -0.6% | +0.1% | +0.3% | — |
| Oct 30, 2024 | TNS | 3.77 | 4.08 | +8.2% | 181.18 | -1.7% | -4.0% | -0.1% | -0.2% | +2.0% | -1.4% | — |
| Aug 1, 2024 | TNS | 4.07 | 5.28 | +29.7% | 210.70 | +0.8% | -2.4% | -3.5% | +0.9% | -0.2% | +2.1% | — |
| Apr 24, 2024 | TNS | 3.47 | 3.67 | +5.8% | 201.99 | -0.4% | +0.2% | +3.2% | +3.2% | -0.3% | +0.6% | — |
| Feb 13, 2024 | TNS | 3.16 | 2.95 | -6.6% | 226.65 | +0.2% | -2.6% | +1.2% | -1.9% | +0.1% | +0.9% | — |
| Nov 8, 2023 | TNS | 3.99 | 4.36 | +9.3% | 231.69 | +0.1% | -3.0% | +0.1% | -1.0% | +1.2% | +1.9% | — |
| Jul 25, 2023 | TNS | 3.77 | 4.02 | +6.6% | 270.31 | -0.1% | -1.9% | -0.9% | +0.9% | +1.9% | -0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 8 | Needham | Upgrade | Hold → Buy | $255 | $195.34 | $197.25 | +1.0% | -1.4% | +3.4% | -2.4% | +2.9% | +0.0% |
| May 15 | Evercore ISI | Reiterates | Outperform | — | $191.37 | $191.83 | +0.2% | +0.8% | -0.5% | -0.7% | -1.4% | +0.9% |
| May 1 | Citigroup | Maintains | Neutral → Neutral | — | $189.28 | $189.28 | +0.0% | -1.2% | +0.1% | +1.0% | +0.8% | +0.4% |
| Apr 30 | Wedbush | Maintains | Neutral → Neutral | — | $194.38 | $194.02 | -0.2% | -2.6% | -1.2% | +0.1% | +1.0% | +0.8% |
| Apr 30 | Guggenheim | Maintains | Buy → Buy | — | $194.38 | $194.02 | -0.2% | -2.6% | -1.2% | +0.1% | +1.0% | +0.8% |
| Apr 30 | RBC Capital | Maintains | Outperform → Outperform | — | $194.38 | $194.02 | -0.2% | -2.6% | -1.2% | +0.1% | +1.0% | +0.8% |
| Apr 30 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $194.38 | $194.02 | -0.2% | -2.6% | -1.2% | +0.1% | +1.0% | +0.8% |
| Apr 22 | UBS | Upgrade | Neutral → Buy | $225 | $185.95 | $189.31 | +1.8% | +2.2% | -1.2% | -1.9% | -2.0% | +1.5% |
| Apr 20 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $177.35 | $179.54 | +1.2% | +3.4% | +1.4% | +2.2% | -1.2% | -1.9% |
| Apr 14 | Piper Sandler | Upgrade | Neutral → Overweight | — | $176.37 | $177.71 | +0.8% | +1.5% | +0.9% | -2.5% | +0.8% | +3.4% |
| Apr 13 | Truist | Maintains | Hold → Hold | — | $172.97 | $172.62 | -0.2% | +2.0% | +1.5% | +0.9% | -2.5% | +0.8% |
| Apr 13 | Citigroup | Maintains | Neutral → Neutral | — | $172.97 | $172.62 | -0.2% | +2.0% | +1.5% | +0.9% | -2.5% | +0.8% |
| Apr 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $177.11 | $177.97 | +0.5% | -2.3% | +2.0% | +1.5% | +0.9% | -2.5% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $183.78 | $181.46 | -1.3% | -3.5% | -2.8% | +1.9% | +2.4% | -1.6% |
| Apr 1 | Oppenheimer | Maintains | Outperform → Outperform | — | $183.33 | $183.16 | -0.1% | +0.2% | -3.5% | -2.8% | +1.9% | +2.4% |
| Apr 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $183.33 | $183.16 | -0.1% | +0.2% | -3.5% | -2.8% | +1.9% | +2.4% |
| Mar 17 | HSBC | Maintains | Reduce → Reduce | — | $183.26 | $184.73 | +0.8% | +1.1% | -1.6% | +0.6% | -1.1% | +1.2% |
| Feb 23 | Freedom Broker | Maintains | Hold → Hold | — | $192.03 | $191.82 | -0.1% | +2.2% | -0.6% | -2.3% | -1.4% | +2.0% |
| Feb 10 | Wedbush | Maintains | Neutral → Neutral | — | $193.81 | $194.07 | +0.1% | -2.5% | +1.2% | +2.2% | +0.5% | -0.5% |
| Feb 9 | Guggenheim | Maintains | Buy → Buy | — | $201.18 | $199.83 | -0.7% | -3.7% | -2.5% | +1.2% | +2.2% | +0.5% |
| Feb 9 | RBC Capital | Maintains | Outperform → Outperform | — | $201.18 | $199.83 | -0.7% | -3.7% | -2.5% | +1.2% | +2.2% | +0.5% |
| Feb 9 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $201.18 | $199.83 | -0.7% | -3.7% | -2.5% | +1.2% | +2.2% | +0.5% |
| Feb 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $201.18 | $199.83 | -0.7% | -3.7% | -2.5% | +1.2% | +2.2% | +0.5% |
| Feb 9 | Truist | Maintains | Hold → Hold | — | $201.18 | $199.83 | -0.7% | -3.7% | -2.5% | +1.2% | +2.2% | +0.5% |
| Feb 9 | Wedbush | Maintains | Neutral → Neutral | — | $201.18 | $199.83 | -0.7% | -3.7% | -2.5% | +1.2% | +2.2% | +0.5% |
| Feb 9 | Piper Sandler | Maintains | Neutral → Neutral | — | $201.18 | $199.83 | -0.7% | -3.7% | -2.5% | +1.2% | +2.2% | +0.5% |
| Feb 9 | JP Morgan | Maintains | Neutral → Neutral | — | $201.18 | $199.83 | -0.7% | -3.7% | -2.5% | +1.2% | +2.2% | +0.5% |
| Feb 9 | Citigroup | Maintains | Neutral → Neutral | — | $201.18 | $199.83 | -0.7% | -3.7% | -2.5% | +1.2% | +2.2% | +0.5% |
| Feb 9 | TD Cowen | Maintains | Buy → Buy | — | $201.18 | $199.83 | -0.7% | -3.7% | -2.5% | +1.2% | +2.2% | +0.5% |
| Feb 9 | BMO Capital | Maintains | Market Perform → Market Perform | — | $201.18 | $199.83 | -0.7% | -3.7% | -2.5% | +1.2% | +2.2% | +0.5% |
| Feb 9 | Canaccord Genuity | Maintains | Buy → Buy | — | $201.18 | $199.83 | -0.7% | -3.7% | -2.5% | +1.2% | +2.2% | +0.5% |
| Jan 30 | Oppenheimer | Maintains | Outperform → Outperform | — | $176.18 | $177.09 | +0.5% | +2.1% | -0.4% | -1.3% | +4.9% | -0.0% |
| Jan 27 | Citigroup | Maintains | Neutral → Neutral | — | $173.12 | $173.02 | -0.1% | +0.6% | +0.4% | +0.8% | +2.1% | -0.4% |
| Jan 8 | Truist | Maintains | Hold → Hold | — | $186.91 | $187.02 | +0.1% | -0.5% | +0.9% | -1.1% | -3.9% | -5.0% |
| Jan 7 | Citigroup | Maintains | Neutral → Neutral | — | $182.61 | $181.70 | -0.5% | +2.4% | -0.5% | +0.9% | -1.1% | -3.9% |
| Dec 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $172.50 | $173.49 | +0.6% | +0.9% | +0.9% | -2.4% | +0.3% | -1.3% |
| Dec 10 | HSBC | Downgrade | Hold → Reduce | — | $175.84 | $173.30 | -1.4% | +1.0% | -2.8% | +0.9% | +0.9% | -2.4% |
| Dec 10 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $175.84 | $173.30 | -1.4% | +1.0% | -2.8% | +0.9% | +0.9% | -2.4% |
| Nov 21 | Piper Sandler | Maintains | Neutral → Neutral | — | $168.18 | $168.54 | +0.2% | +4.2% | +0.9% | +2.9% | -0.0% | +0.1% |
| Nov 6 | Stifel | Upgrade | Hold → Buy | — | $153.43 | $155.76 | +1.5% | +2.2% | -0.8% | +0.5% | +2.1% | +1.2% |
| Nov 6 | Freedom Broker | Downgrade | Buy → Hold | — | $153.43 | $155.76 | +1.5% | +2.2% | -0.8% | +0.5% | +2.1% | +1.2% |
| Nov 3 | Bernstein | Maintains | Market Perform → Market Perform | — | $154.27 | $153.60 | -0.4% | -1.8% | -1.4% | +2.7% | +2.2% | -0.8% |
| Oct 31 | RBC Capital | Maintains | Outperform → Outperform | — | $149.61 | $147.99 | -1.1% | +3.1% | -1.8% | -1.4% | +2.7% | +2.2% |
| Oct 14 | Citigroup | Maintains | Neutral → Neutral | — | $144.69 | $144.09 | -0.4% | +0.4% | -1.1% | -1.0% | +0.5% | +2.5% |
| Oct 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $149.61 | $150.00 | +0.3% | -2.0% | -1.3% | +0.4% | -1.1% | -1.0% |
| Sep 24 | Needham | Maintains | Hold → Hold | — | $139.31 | $138.52 | -0.6% | -1.2% | -1.5% | +1.3% | +0.8% | +1.1% |
| Sep 4 | Needham | Maintains | Hold → Hold | — | $141.62 | $141.78 | +0.1% | -1.2% | +0.5% | +0.5% | +1.6% | -0.7% |
| Aug 14 | Piper Sandler | Maintains | Neutral → Neutral | — | $135.19 | $134.51 | -0.5% | -0.2% | +2.7% | -1.9% | +2.2% | +0.1% |
| Aug 1 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $128.00 | $128.96 | +0.8% | +3.1% | +0.2% | +0.5% | -2.7% | -1.2% |
| Aug 1 | RBC Capital | Maintains | Outperform → Outperform | — | $128.00 | $128.96 | +0.8% | +3.1% | +0.2% | +0.5% | -2.7% | -1.2% |
No insider trades available.
8-K
Biogen Inc. -- 8-K Filing
Jun 10
8-K
Biogen Inc. -- 8-K Filing
May 14
8-K
Biogen Inc. -- 8-K Filing
Biogen demonstrated strong financial momentum with Non-GAAP EPS growing 31% year-over-year and LEQEMBI sales surging 74%, signaling successful commercial execution across its neurology portfolio.
Apr 29
8-K
Unknown — 8-K Filing
This standard safe harbor language indicates Biogen is protecting itself from litigation over forward-looking statements, suggesting management made optimistic projections investors should scrutinize carefully for accuracy.
Apr 6
8-K
Unknown — 8-K Filing
Biogen is acquiring Apellis for an upfront payment plus contingent value rights, signaling aggressive expansion into complement-driven therapies and providing Apellis shareholders a defined exit with potential earn-out upside.
Mar 31
8-K
Unknown — 8-K Filing
I need more substantive information from the 8-K filing to provide meaningful analysis. The summary provided only contains technical metadata about the document format rather than actual business content or events that would impact BIIB's stock.
Could you provide the actual filing details, such as material events, executive changes, financial updates, or strategic announcements?
Mar 11
8-K
Biogen Inc. -- 8-K Filing
I cannot provide a meaningful analysis of this filing as the summary contains only technical XBRL metadata and schema references without substantive business information about Biogen's actions or events.
Feb 11
8-K
Biogen Inc. -- 8-K Filing
Biogen's SKYCLARYS generated $78 million in global sales with 30% patient growth in Q4 2025, signaling strong commercial traction for this rare disease treatment.
Feb 6
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Primecap Management Co/ca/ | 14,757,607 | $2.7B | — | Mar 2026 |
| 2 | Fmr Llc | 12,807,541 | $2.3B | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 9,537,417 | $1.7B | New | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 6,531,727 | $1.2B | New | Mar 2026 |
| 5 | Morgan Stanley | 4,650,026 | $818M | Added | Dec 2025 |
| 6 | Jpmorgan Chase & Co | 2,016,009 | $378M | Added | Mar 2026 |
| 7 | Aqr Capital Management Llc | 1,923,557 | $346M | Added | Mar 2026 |
| 8 | Invesco Ltd. | 1,745,255 | $320M | Added | Mar 2026 |
| 9 | Boston Partners | 1,700,078 | $312M | Reduced | Mar 2026 |
| 10 | Northern Trust Corp | 1,446,579 | $265M | — | Mar 2026 |
| 11 | Bank Of America Corp /de/ | 1,156,369 | $212M | Reduced | Mar 2026 |
| 12 | Pictet Asset Management Holding Sa | 947,494 | $167M | Added | Dec 2025 |
| 13 | Point72 Asset Management | 809,617 | $148M | Reduced | Mar 2026 |
| 14 | Alyeska Investment Group, L.p. | 805,050 | $148M | Reduced | Mar 2026 |
| 15 | Amundi | 790,827 | $145M | New | Mar 2026 |
| 16 | Bank Of New York Mellon Corp | 788,523 | $145M | Reduced | Mar 2026 |
| 17 | Robeco Institutional Asset Management B.v. | 763,174 | $140M | Added | Mar 2026 |
| 18 | Employees Provident Fund Board | 704,196 | $129M | — | Mar 2026 |
| 19 | First Trust Advisors Lp | 673,958 | $124M | Added | Mar 2026 |
| 20 | Artemis Investment Management Llp | 571,571 | $105M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$29.02B
Enterprise Value
$31.60B
P/E (TTM)
22.26x
Forward P/E
13.35x
PEG Ratio
-0.95x
P/B
1.58x
P/S
2.94x
P/FCF
14.06x
EV/EBITDA
10.19x
Shares Out
146.7M
Financials (TTM)
Revenue
$9.81B
Net Income
$1.29B
EBITDA
$3.10B
Free Cash Flow
$2.05B
Op Cash Flow
$2.20B
EPS Basic
$8.85
EPS Diluted
$8.83
EPS Forward
$14.73
Gross Margin
70.5%
Op Margin
19.1%
Net Margin
13.2%
Balance Sheet
Total Assets
$29.44B
Total Liab.
$11.18B
Total Equity
$18.26B
Cash
$3.82B
LT Debt
$6.58B
Book Value/Sh
$124.45
Debt/Equity
0.38x
Current Ratio
2.68
Quick Ratio
2.03
Returns & Growth
ROE
9.3%
ROA
4.7%
ROIC
6.6%
Rev Growth YoY
+1.4%
EPS Growth YoY
-21.0%
Price Returns
2W
+2.4%
1M
+3.6%
3M
+2.2%
6M
+7.6%
12M
+51.0%
Technicals
52W High
$205.97
52W Low
$121.05
50d MA
$190.48
200d MA
$174.70
RSI (14)
50.60
ATR (14)
$6.03
Beta
0.16
Avg Volume
1.1M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$213.35
High
$260.00
Low
$143.00
Median
$218.00
Data updated apr 24, 2026 9:37pm
· Source: financialmodelingprep.com